Press Release

Parkinson’s Disease Drugs Market 2019 Significant Growth Rate by Industry Size, Share, Market Dynamics, Development Status of Key Players Forecast to 2024

Parkinson’s

The “Parkinson’s Disease Drugs Market” research report 2019 delivers comprehensive information about the market ranging from the establishment to the predictable growth trend. Parkinson’s Disease Drugs market report provides brief analytical data of the market contenders globally using advanced methodological approaches, such as SWOT analysis, production chain, cost, sales margin, financial details, recent developments. Parkinson’s Disease Drugs market report also offers market competitors that includes detailed company profiles along with company product specifications.

Market Overview:

  • Parkinson’s disease is a chronic disorder that gradually leads to progressive deterioration of motor functions, caused by the loss of dopamine-producing brain cells. Parkinson’s disease drugs market is expected to witness significant growth, owing to the increasing cases of Parkinson’s disease, with the growth in aging population levels. Therefore, it may drastically result in increasing the market size during the forecast period. Pharmaceutical firms are developing new and improved therapies for Parkinson’s disease (PD), and recently, there have been some major product launches in Parkinson disease therapeutics and other assistive therapeutics. For instance, Adamas Pharmaceuticals’ amantadine extended-release capsules / Gocovri launched in Jan 2018, which was the first drug indicated for dyskinesia developed due to long-term use of levodopa. Furthermore, most of the global firms have a robust drug pipeline for the treatment of Parkinson’s disease, and as per the estimates, the forecast period may witness the launch of a few blockbuster drugs.

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/14099025

    In Parkinson’s Disease Drugs Market Report, Following Companies Are Covered:

  • Merck & Co. Inc.
  • Impax Laboratories Inc.
  • AbbVie Inc.
  • Mylan NV
  • Boehringer Ingelheim
  • GlaxoSmithKline plc
  • M Somerset Pharmaceuticals Inc.
  • Teva Pharmaceuticals Industries Ltd
  • Pfizer Inc.
  • Novartis AG

    Parkinson’s Disease Drugs Market 2019 report will help the industry aspirants in arranging their strategies. The measurements offered in this report will be an exact and helpful manual to shape the business development. Additionally, will Provide historical data along with a future forecast and detailed analysis and also expected opportunities.

    Scope of the Report:

  • Parkinson’s disease drugs market has been segmented by the mechanism of action and geography. BY mechanism of action, the market studied is segmented into dopamine agonists, anticholinergic, MAO-B inhibitors, amantadine, carbidopa-levodopa, COMT inhibitors, and other mechanisms of action. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

    Reasons for Buying Parkinson’s Disease Drugs Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/14099025

    Key Market Trends:

    COMT (Catechol-O-Methyltransferase) Inhibitors are expected to Register Robust growth

    Carbidopa-levodopa Therapy is the most effective medication for alleviating the motor symptoms of PD. However, it has been observed that this medication is not as effective as intended. Therefore, it is imperative that co-therapeutic agents, such as COMT (catechol-O-methyltransferase) inhibitors, are used along with carbidopa-levodopa therapy. The two most common COMT inhibitors, used in the treatment of Parkinson’s disease, are Comtan (entacapone) and Tasmar (tolcapone). Both these medications are available in the form of tablets. In addition, these medications are routinely prescribed in conjunction with carbidopa-levodopa therapy.

    The United States Represents the Largest Market for Parkinson’s Disease Therapeutics

    According to the National Institute of Health, approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by 2030. It is the second-most common neurodegenerative disorder in the United States. In addition, there are thousands of patients who go undetected. As the aging population levels continue to grow, the number of people suffering from Parkinson’s disease (PD) will continue to grow, and this is expected to double by 2040. The sheer number of Parkinson’s disease patients, combined with the availability of reimbursements and high awareness, is boosting the growth of the market. Furthermore, the high cost of Parkinson’s disease therapeutics in the United States also leads to significant market size in terms of revenue. The average cost of Parkinson’s medication is approximately USD 2,500 per year and Parkinson’s-related surgery can cost up to USD 100,000 per patient.

    The Research Document Will Answer Following Questions Such as:

    • What are the cutting-edge technologies responsible for driving the growth of the market?
    • What are the main applications of the market? What are the growth prospects to the market applications into the market?
    • At what stage of development are the key market products?
    • What are the shortcomings that has to face to become commercially viable? Is their growth and commercialization dependent on cost declines or technological/application breakthroughs?
    • What is the outlook for the industry?
    • What difference does performance characteristics of Parkinson’s Disease Drugs create from those of established entities?

    Purchase this Report (Price 4250 USD for single user license) – https://www.industryresearch.co/purchase/14099025

    Detailed TOC of Parkinson’s Disease Drugs Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Rising Geriatric Population
    4.2.2 Recent Drug Approvals
    4.2.3 Growing Awareness
    4.3 Market Restraints
    4.3.1 Generic Competition to Key Therapies
    4.3.2 High Cost of Treatment
    4.4 Porter’s Five Forces Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Mechanism of Action
    5.1.1 Dopamine Agonists
    5.1.2 Anticholinergic
    5.1.3 MAO-B inhibitors
    5.1.4 Amantadine
    5.1.5 Carbidopa-levodopa
    5.1.6 COMT Inhibitors
    5.1.7 Other Mechanisms of Action
    5.2 Geography
    5.2.1 North America
    5.2.1.1 US
    5.2.1.2 Canada
    5.2.1.3 Mexico
    5.2.2 Europe
    5.2.2.1 Germany
    5.2.2.2 UK
    5.2.2.3 France
    5.2.2.4 Italy
    5.2.2.5 Spain
    5.2.2.6 Rest of Europe
    5.2.3 Asia-Pacific
    5.2.3.1 China
    5.2.3.2 Japan
    5.2.3.3 India
    5.2.3.4 Australia
    5.2.3.5 South Korea
    5.2.3.6 Rest of Asia-Pacific
    5.2.4 Middle East & Africa
    5.2.4.1 GCC
    5.2.4.2 South Africa
    5.2.4.3 Rest of Middle East & Africa
    5.2.5 South America
    5.2.5.1 Brazil
    5.2.5.2 Argentina
    5.2.5.3 Rest of South America

    6 COMPETITIVE LANDSCAPE
    6.1 Company Profiles
    6.1.1 Merck & Co. Inc.
    6.1.2 Impax Laboratories Inc.
    6.1.3 AbbVie Inc.
    6.1.4 Mylan NV
    6.1.5 Boehringer Ingelheim
    6.1.6 GlaxoSmithKline plc
    6.1.7 M Somerset Pharmaceuticals Inc.
    6.1.8 Teva Pharmaceuticals Industries Ltd
    6.1.9 Pfizer Inc.
    6.1.10 Novartis AG

    7 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Global Bacillus Coagulans Market Share, Size 2019 – Industry Future Demand, Worldwide Research, Top Leading Players, Emerging Trends, Region by Forecast to 2024

    Metal Implants and Medical Alloys Market 2019 Global Manufacturing Size, Share, Opportunities, Future Trends, Top Key Players, Market Share and Global Analysis by Forecast to 2024

    Subsea Vessel Market Current Status 2019 | Size, Share, Trend, Global Demand, Top Companies, Product Category and Forecast to 2023

    Global Submarine Sensors Market 2019 – Industry Analysis by Top Key Players, Key Countries, Market Size & Share, Growth Rate Forecast to 2023

    Tags
  • Alfredoo Epps

    Alfredo Epps is a finance expert heading the petroleum column. He joined the group last year as an associate writer. But his thorough research skills and ability to seamlessly putting numerical data into words helped him get a senior position. Apart from a column head, Alfredo is a dancer and a violinist.

    Related Articles

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    Close